• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MannKind Corporation

    4/1/25 5:02:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email
    DEFA14A 1 mnkd_defa_14a_2025.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    (RULE 14a-101)

    INFORMATION REQUIRED IN

    PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

     

     

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

     ☐

    ​

    ​

    Preliminary Proxy Statement

     ☐

    ​

    ​

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    ​

    ​

    Definitive Proxy Statement

     ☒

    ​

    ​

    Definitive Additional Materials

     ☐

    ​

    ​

    Soliciting Material Pursuant to § 240.14a-12

     

    MANNKIND CORPORATION

    (Name of Registrant as Specified in its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

     

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

     

    Your Vote Counts! MANNKIND CORPORATION 2024 Annual Meeting Vote by May 14, 2024 11:59 PM ET Company Logo 1 CASPER STREET DANBURY, CT 06810 V45604-P05211 You invested in MANNKIND CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 15, 2024. Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 1, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* May 15, 2024 10:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/MNKD2024 For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* May 15, 2024 10:00 AM EDT Virtually at: www.virtualshareholdermeeting.com/MNKD2024 *Please check the meeting materials for any special requirements for meeting attendance.img107523360_0.jpg


     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1.To elect the nine nominees named herein as directors to serve for the ensuing year and img107523360_1.jpguntil their successors are elected; Nominees: 01)James S. Shannon, M.D., MRCP (UK)06) Anthony Hooper02) Michael E. Castagna, Pharm.D.07) Sabrina Kay, Ed.D.03) Ronald J. Consiglio08) Kent Kresa04) Michael A. Friedman, M.D.09) Christine Mundkur05) Jennifer Grancio For 2.To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; For 3.To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2024; and For 4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V45605-P05211


    Get the next $MNKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    12/20/2024$9.00Overweight
    Wells Fargo
    12/19/2024$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    9/9/2024$7.00 → $8.00Outperform
    Leerink Partners
    6/13/2024$8.00Buy
    Rodman & Renshaw
    10/10/2023$10.00Outperform
    Wedbush
    2/28/2022$6.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MannKind to Present at Upcoming Investor Conferences

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: RBC Capital Markets 2025 Global Annual Healthcare Conference Tuesday, May 20, 8:00 a.m. ET Jefferies Global Healthcare Conference Thursday, June 5,

      5/13/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Castagna Michael was granted 27,000 shares, increasing direct ownership by 1% to 2,639,048 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/16/25 6:20:59 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres, Endocrine Business Unit Marasco Dominic was granted 81,429 shares, increasing direct ownership by 32% to 333,429 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/16/25 6:20:27 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hooper Anthony C was granted 25,000 shares, increasing direct ownership by 14% to 201,153 units (SEC Form 4)

      4 - MANNKIND CORP (0000899460) (Issuer)

      5/16/25 6:10:21 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    See more
    • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

      MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

      1/5/22 6:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    SEC Filings

    See more
    • SEC Form 8-K filed by MannKind Corporation

      8-K - MANNKIND CORP (0000899460) (Filer)

      5/15/25 4:08:08 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by MannKind Corporation

      144 - MANNKIND CORP (0000899460) (Subject)

      5/13/25 4:02:55 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MannKind Corporation

      10-Q - MANNKIND CORP (0000899460) (Filer)

      5/8/25 8:10:25 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Financials

    Live finance-specific insights

    See more
    • MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y

      5/8/25 8:05:00 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

      DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2

      5/1/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

      2/26/25 4:05:00 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/13/24 5:08:11 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      1/22/24 12:56:57 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

      SC 13G/A - MANNKIND CORP (0000899460) (Subject)

      2/9/23 11:25:13 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Mannkind with a new price target

      Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00

      4/10/25 12:42:30 PM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Mannkind with a new price target

      Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00

      2/10/25 7:01:41 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Mannkind with a new price target

      Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00

      12/20/24 7:44:06 AM ET
      $MNKD
      Biotechnology: Pharmaceutical Preparations
      Health Care